Cargando…
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer
BACKGROUND: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (N+) breast cancers by means of a microarray study. The aim of this study was to validate UBE2C protein as a prognostic marker in N+ breast cancer by immunohistochemistry (IHC). METHODS: To this en...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713693/ https://www.ncbi.nlm.nih.gov/pubmed/19513072 http://dx.doi.org/10.1038/sj.bjc.6605122 |
_version_ | 1782169598831886336 |
---|---|
author | Loussouarn, D Campion, L Leclair, F Campone, M Charbonnel, C Ricolleau, G Gouraud, W Bataille, R Jézéquel, P |
author_facet | Loussouarn, D Campion, L Leclair, F Campone, M Charbonnel, C Ricolleau, G Gouraud, W Bataille, R Jézéquel, P |
author_sort | Loussouarn, D |
collection | PubMed |
description | BACKGROUND: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (N+) breast cancers by means of a microarray study. The aim of this study was to validate UBE2C protein as a prognostic marker in N+ breast cancer by immunohistochemistry (IHC). METHODS: To this end, 92 paraffin-embedded blocks were used. The impact of UBE2C IHC value on metastasis-free survival (MFS) and overall survival (OS) was evaluated and compared with Ki-67 and Nottingham prognostic index (NPI) performances. RESULTS: In accordance with genomic data, UBE2C IHC had a significant impact both on MFS and OS (hazard ratio=6.79 – P=0.002; hazard ratio=7.14 – P=0.009, respectively). Akaike information criterion proved that the prognostic power of UBE2C IHC was stronger than that of Ki-67 (and close to that of NPI). Furthermore, multivariate analyses with NPI showed that, contrary to Ki-67 IHC, UBE2C IHC remained an independent factor, both for MFS (adjusted P=0.02) and OS (adjusted P=0.04). CONCLUSION: We confirmed that UBE2C protein measured by IHC could be used as a prognostic marker in N+ breast cancer. The potential predictive interest of UBE2C as a marker of proteasome activity needs further investigations. |
format | Text |
id | pubmed-2713693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27136932010-07-07 Validation of UBE2C protein as a prognostic marker in node-positive breast cancer Loussouarn, D Campion, L Leclair, F Campone, M Charbonnel, C Ricolleau, G Gouraud, W Bataille, R Jézéquel, P Br J Cancer Molecular Diagnostics BACKGROUND: We recently identified and validated UBE2C RNA as a prognostic marker in 252 node-positive (N+) breast cancers by means of a microarray study. The aim of this study was to validate UBE2C protein as a prognostic marker in N+ breast cancer by immunohistochemistry (IHC). METHODS: To this end, 92 paraffin-embedded blocks were used. The impact of UBE2C IHC value on metastasis-free survival (MFS) and overall survival (OS) was evaluated and compared with Ki-67 and Nottingham prognostic index (NPI) performances. RESULTS: In accordance with genomic data, UBE2C IHC had a significant impact both on MFS and OS (hazard ratio=6.79 – P=0.002; hazard ratio=7.14 – P=0.009, respectively). Akaike information criterion proved that the prognostic power of UBE2C IHC was stronger than that of Ki-67 (and close to that of NPI). Furthermore, multivariate analyses with NPI showed that, contrary to Ki-67 IHC, UBE2C IHC remained an independent factor, both for MFS (adjusted P=0.02) and OS (adjusted P=0.04). CONCLUSION: We confirmed that UBE2C protein measured by IHC could be used as a prognostic marker in N+ breast cancer. The potential predictive interest of UBE2C as a marker of proteasome activity needs further investigations. Nature Publishing Group 2009-07-07 2009-06-09 /pmc/articles/PMC2713693/ /pubmed/19513072 http://dx.doi.org/10.1038/sj.bjc.6605122 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Loussouarn, D Campion, L Leclair, F Campone, M Charbonnel, C Ricolleau, G Gouraud, W Bataille, R Jézéquel, P Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title | Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title_full | Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title_fullStr | Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title_full_unstemmed | Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title_short | Validation of UBE2C protein as a prognostic marker in node-positive breast cancer |
title_sort | validation of ube2c protein as a prognostic marker in node-positive breast cancer |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713693/ https://www.ncbi.nlm.nih.gov/pubmed/19513072 http://dx.doi.org/10.1038/sj.bjc.6605122 |
work_keys_str_mv | AT loussouarnd validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT campionl validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT leclairf validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT camponem validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT charbonnelc validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT ricolleaug validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT gouraudw validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT batailler validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer AT jezequelp validationofube2cproteinasaprognosticmarkerinnodepositivebreastcancer |